This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Barrack, Rodos & Bacine Files Securities Law Class Action Lawsuit Against Nu Skin Enterprises, Inc.

Stocks in this article: NUS

PHILADELPHIA, Jan. 21, 2014 /PRNewswire/ -- Barrack, Rodos & Bacine announces that it has filed a class action lawsuit in the United States District Court for the District of Utah, Freedman v. Nu Skin Enterprises, Inc., et al., Civil Action No. 2:14-cv-00033-PMW, on behalf of purchasers of common stock of Nu Skin Enterprises, Inc. (NYSE: NUS) ("Nu Skin" or the "Company") during the period from July 10, 2013 through and including January 14, 2014 (the "Class Period").

Nu Skin is a global direct selling company with operations in 53 markets worldwide.  The Company purports to develop and distribute premium quality anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands.  The Company's global operations generated more than $2.17 billion in revenue during 2012.

The complaint alleges that during the Class Period, defendants issued a series of false and misleading statements concerning the Company's business practices and growth prospects, particularly with respect to its Mainland China operations, upon which the Company has become very dependent for a very significant amount of its revenue and growth.  Sales in Mainland China accounted for nearly one third of the Company's total revenue in the first nine months of 2013.  Further, the complaint alleges that while the Company issued public statements discussing its positive results and increased guidance, it failed to disclose what are alleged to be fraudulent sales practices and non-compliance with laws and regulations in China, or their potential impact on the Company.  Then, in January 2014, two Chinese agencies announced that they are probing the Company's marketing and business practices in China and that it was suspected the Company was operating as an illegal pyramid scheme.  These revelations had an immediate impact on the Company's stock price, causing shares of Nu Skin's stock, which had risen from less than $70 per share to a high of $140.50 per share during the Class Period, to tumble over 44% in the two days of trading after these announcements.  Nu Skin stock closed the trading day on January 17, 2014 at less than $80 per share. 

Plaintiff seeks to recover damages on behalf of all purchasers of common stock of Nu Skin during the Class Period.  The plaintiff is represented by the Philadelphia-based firm of Barrack, Rodos & Bacine and by the Salt Lake City-based firm of Karrenberg & Anderson, both of which have significant experience in prosecuting class actions on behalf of investors in cases involving financial and corporate fraud.

If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2014.  To discuss your rights regarding the appointment of lead plaintiff and for additional information about your interest in this class action, please contact plaintiff's counsel, Barrack, Rodos & Bacine, at the following toll-free number: 877-386-3304, or via e-mail to Jeffrey W. Golan ( jgolan@barrack.com) or Julie B. Palley ( jpalley@barrack.com).  A copy of the complaint is available from the Court or from Barrack, Rodos & Bacine. 

www.barrack.com

SOURCE Barrack, Rodos & Bacine

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs